Alkermes' Vivitrol treats opioid dependence in study
Alkermes' Vivitrol (naltrexone for extended-release injectable suspension) has demonstrated sustained efficacy and safety over 18 months of treatment and supported its clinical ability as a treatment option for opioid dependence following opioid deto…Post to:Deliciousnbsp;nbsp;Diggnbsp;nbsp;redditnbsp;nbsp;Facebooknbsp;nbsp;StumbleUponnbsp;nbsp; (Source: Pharmaceutical Technology)
Effect of night smoking, sleep disturbance, and their co-occurrence on smoking outcomes.
Recent evidence suggests that smoking during the night is an indicator of nicotine dependence and predicts smoking cessation failure. Night smokers are likely to experience disturbance to their sleep cycle when they wake to smoke, but we are not aware of the prevalence of night smokers' self-reported sleep disturbance. Because sleep disturbance also predicts smoking cessation failure, we examined how the pre-cessation risk factors of night smoking and sleep disturbance, and their co-occurrence, predict smoking cessation failure in a 6-week double-blind randomized controlled trial examining whether naltrexone augments the efficacy of the nicotine patch (O'Malley et al., 2006). Smokers (N = 385) completed the Pittsburgh Sleep Quality Index (Buysse, Reynolds, Monk, Berman, Kupfer, 1989) and...
